Global Nanomaterial-Based Adjuvants Vaccine Industry Growth and Trends Forecast to 2031

Summary

According to APO Research, The global Nanomaterial-Based Adjuvants Vaccine market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Nanomaterial-Based Adjuvants Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Nanomaterial-Based Adjuvants Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Nanomaterial-Based Adjuvants Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, Sanofi, GlaxoSmithKline Biologicals, Merck, Pfizer, Novartis and Moderna, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Nanomaterial-Based Adjuvants Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nanomaterial-Based Adjuvants Vaccine.

The Nanomaterial-Based Adjuvants Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Nanomaterial-Based Adjuvants Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Nanomaterial-Based Adjuvants Vaccine Segment by Company

Emergent BioSolutions
Sanofi
GlaxoSmithKline Biologicals
Merck
Pfizer
Novartis
Moderna

Nanomaterial-Based Adjuvants Vaccine Segment by Type

Aluminium Hydroxides
Aluminium Phosphate
Lipidosome
Others

Nanomaterial-Based Adjuvants Vaccine Segment by Application

Pneumococcus
Human Papilloma Virus
DTaP
Viral Hepatitis TypeA
Viral Hepatitis TypeB
SARS-CoV-2
Others

Nanomaterial-Based Adjuvants Vaccine Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanomaterial-Based Adjuvants Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nanomaterial-Based Adjuvants Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanomaterial-Based Adjuvants Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Nanomaterial-Based Adjuvants Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Nanomaterial-Based Adjuvants Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales Estimates and Forecasts (2020-2031)
1.3 Nanomaterial-Based Adjuvants Vaccine Market by Type
1.3.1 Aluminium Hydroxides
1.3.2 Aluminium Phosphate
1.3.3 Lipidosome
1.3.4 Others
1.4 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Type
1.4.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size Overview by Type (2020-2031)
1.4.2 Global Nanomaterial-Based Adjuvants Vaccine Historic Market Size Review by Type (2020-2025)
1.4.3 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Type (2020-2025)
1.5.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Type (2020-2025)
1.5.4 South America Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends
2.2 Nanomaterial-Based Adjuvants Vaccine Industry Drivers
2.3 Nanomaterial-Based Adjuvants Vaccine Industry Opportunities and Challenges
2.4 Nanomaterial-Based Adjuvants Vaccine Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Nanomaterial-Based Adjuvants Vaccine Revenue (2020-2025)
3.2 Global Top Players by Nanomaterial-Based Adjuvants Vaccine Sales (2020-2025)
3.3 Global Top Players by Nanomaterial-Based Adjuvants Vaccine Price (2020-2025)
3.4 Global Nanomaterial-Based Adjuvants Vaccine Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Nanomaterial-Based Adjuvants Vaccine Major Company Production Sites & Headquarters
3.6 Global Nanomaterial-Based Adjuvants Vaccine Company, Product Type & Application
3.7 Global Nanomaterial-Based Adjuvants Vaccine Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Nanomaterial-Based Adjuvants Vaccine Market CR5 and HHI
3.8.2 Global Top 5 and 10 Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue in 2024
3.8.3 2023 Nanomaterial-Based Adjuvants Vaccine Tier 1, Tier 2, and Tier 3
4 Nanomaterial-Based Adjuvants Vaccine Regional Status and Outlook
4.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Nanomaterial-Based Adjuvants Vaccine Historic Market Size by Region
4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Region (2020-2025)
4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales in Value by Region (2020-2025)
4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Market Size by Region
4.3.1 Global Nanomaterial-Based Adjuvants Vaccine Sales in Volume by Region (2026-2031)
4.3.2 Global Nanomaterial-Based Adjuvants Vaccine Sales in Value by Region (2026-2031)
4.3.3 Global Nanomaterial-Based Adjuvants Vaccine Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Nanomaterial-Based Adjuvants Vaccine by Application
5.1 Nanomaterial-Based Adjuvants Vaccine Market by Application
5.1.1 Pneumococcus
5.1.2 Human Papilloma Virus
5.1.3 DTaP
5.1.4 Viral Hepatitis TypeA
5.1.5 Viral Hepatitis TypeB
5.1.6 SARS-CoV-2
5.1.7 Others
5.2 Global Nanomaterial-Based Adjuvants Vaccine Market Size by Application
5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Market Size Overview by Application (2020-2031)
5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Historic Market Size Review by Application (2020-2025)
5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Application (2020-2025)
5.3.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Application (2020-2025)
5.3.4 South America Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Emergent BioSolutions
6.1.1 Emergent BioSolutions Comapny Information
6.1.2 Emergent BioSolutions Business Overview
6.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.1.5 Emergent BioSolutions Recent Developments
6.2 Sanofi
6.2.1 Sanofi Comapny Information
6.2.2 Sanofi Business Overview
6.2.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.2.5 Sanofi Recent Developments
6.3 GlaxoSmithKline Biologicals
6.3.1 GlaxoSmithKline Biologicals Comapny Information
6.3.2 GlaxoSmithKline Biologicals Business Overview
6.3.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.3.5 GlaxoSmithKline Biologicals Recent Developments
6.4 Merck
6.4.1 Merck Comapny Information
6.4.2 Merck Business Overview
6.4.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.4.5 Merck Recent Developments
6.5 Pfizer
6.5.1 Pfizer Comapny Information
6.5.2 Pfizer Business Overview
6.5.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.5.5 Pfizer Recent Developments
6.6 Novartis
6.6.1 Novartis Comapny Information
6.6.2 Novartis Business Overview
6.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.6.5 Novartis Recent Developments
6.7 Moderna
6.7.1 Moderna Comapny Information
6.7.2 Moderna Business Overview
6.7.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio
6.7.5 Moderna Recent Developments
7 North America by Country
7.1 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country
7.1.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025)
7.1.3 North America Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2026-2031)
7.2 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
7.2.1 North America Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Nanomaterial-Based Adjuvants Vaccine Market Size by Country (2020-2025)
7.2.3 North America Nanomaterial-Based Adjuvants Vaccine Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country
8.1.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025)
8.1.3 Europe Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2026-2031)
8.2 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country
8.2.1 Europe Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Nanomaterial-Based Adjuvants Vaccine Market Size by Country (2020-2025)
8.2.3 Europe Nanomaterial-Based Adjuvants Vaccine Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Country
9.1.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025)
9.1.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Country
9.2.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Nanomaterial-Based Adjuvants Vaccine Sales by Country
10.1.1 South America Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025)
10.1.3 South America Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2026-2031)
10.2 South America Nanomaterial-Based Adjuvants Vaccine Market Size by Country
10.2.1 South America Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Nanomaterial-Based Adjuvants Vaccine Market Size by Country (2020-2025)
10.2.3 South America Nanomaterial-Based Adjuvants Vaccine Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country
11.1.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2020-2025)
11.1.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country
11.2.1 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Nanomaterial-Based Adjuvants Vaccine Value Chain Analysis
12.1.1 Nanomaterial-Based Adjuvants Vaccine Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process
12.2 Nanomaterial-Based Adjuvants Vaccine Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Nanomaterial-Based Adjuvants Vaccine Distributors
12.2.3 Nanomaterial-Based Adjuvants Vaccine Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings